SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
January 26, 2001
----------------
Date of Report
(Date of earliest event reported)
BioSyntech, Inc.
----------------
(Exact Name of Registrant as Specified in Charter)
Nevada 0-27179 88-0329399
-------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
475 Boulevard Armand-Frappier, Laval, Quebec, Canada H7V 4B3
- -------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(450) 686-2437
--------------
(Registrant's telephone number,
including area code)
----------------------------
(Former Name or Former Address, if Changed Since Last Report.)
Item 5. Other Events.
------------
On January 26, 2001, BioSyntech, Inc. issued the press release
annexed as an exhibit hereto, which is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information
-----------------------------------------------------
and Exhibits.
-------------
(c) Exhibits
Exhibit No. Descriution
----------- -----------
99.1 Press Release dated January 26, 2001
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BioSyntech, Inc.
Dated: January 30, 2001 By: /s/ Anthony Casola
-----------------------------------------
Name: Anthony Casola
Title: Chief Financial Officer &
Secretary
Exhibit 99.1
Friday January 26, 7:17 am Eastern Time
Press Release
Update on Current Activities at BIOSYNTECH Inc.
QUEBEC--(BUSINESS WIRE)--Jan. 26, 2001--BIOSYNTECH (OTCBB:BSYI -news)
BIOSYNTECH Inc. announced that they are in advanced discussions with several
biomedical and pharmaceutical companies to license and co-develop some of
BIOSYNTECH's products as well as to form strategic alliances for the
co-development of their tissue engineering products and instrumentation lines.
The company intends to formalize these discussions within a short period of
time.
Additionally, BIOSYNTECH Inc. announced that Marie-Claire Pilon who held the
position of Chief Executive Officer and a Director of the company, has decided
to leave the company to pursue other interests. Amine Selmani, Ph.D., the
Company's Chairman of the Board and President, will assume the responsibilities
of Chief Executive Officer. BIOSYNTECH Inc. also confirms the nomination of Dr.
Ajay Gupta as Chief Operating Officer (COO), reporting directly to the Chief
Executive Officer and President of the company. Dr. Gupta holds a Ph.D. in
synthetic organic chemistry from University of Waterloo and has a vast
experience in drug discovery and in drug development in various pharmaceutical
companies.
BIOSYNTECH is an advanced biomaterials company specialising in tissue
engineering and in the delivery of advanced injectable biomaterials and
biotherapeutic agents.
This press release contains certain "forward-looking" statements, as defined in
the United States Private Securities Litigation Reform Act of 1995 that involve
a number of risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and the actual results and future events
could differ materially from management's current expectations. Such factors are
detailed from time to time in the company's filings with the regulatory
authorities having jurisdiction.
No regulatory authority has approved or disapproved the content of this release.
Contact:
BIOSYNTECH Inc.
Amine Selmani, 450/686-2437
E-mail: selmani@biosyntech.com